The research team, led by Yamin Li and colleagues, analyzed 615 patients with pathologically confirmed papillary thyroid carcinoma who underwent total or near-total thyroidectomy with lymph node dissection followed by their first course of radioactive iodine ablation. The cohort included 189 men and 426 women ranging from 16 to 80 years of age, with a mean age of about 42 years. Using the 2025 American Thyroid Association recurrence-risk framework, the investigators re-stratified the patients into low/low-to-intermediate and intermediate-high/high risk categories, deliberately excluding anyone with distant metastases at baseline so that “high risk” in this cohort reflected only loco-regional disease features such as gross extrathyroidal extension, extranodal extension, bulky nodal disease, or aggressive histology.

Treatment response was assessed six months after iodine-131 therapy, a time point consistent with the ATA’s dynamic risk assessment system, using suppressed thyroglobulin, thyroglobulin antibody levels, diagnostic whole-body scintigraphy, and SPECT/CT imaging. Patients were classified into four categories: excellent response, indeterminate response, biochemical incomplete response, and structural incomplete response—the latter defined by suspicious imaging findings or biopsy-proven local or distant metastatic disease. For analytical purposes, the first three categories were grouped together as non-SIR. The contrast between risk strata was striking: structural incomplete response occurred in just 10.4 percent of low/low-to-intermediate risk patients but in 38.1 percent of the intermediate-high/high risk group, a difference the authors describe as highly statistically significant.

Digging deeper into each stratum, the researchers found that the determinants of treatment failure differed markedly depending on baseline risk. In the lower-risk group, univariate analysis flagged stimulated thyroglobulin, the presence of lymph node metastasis, thyroglobulin antibody levels, and the administered iodine-131 dose as significant factors, while gender, T stage, the number of lymph nodes removed, the lymph node ratio, and age showed no association. Receiver operating characteristic analysis identified optimal predictive cutoffs of 1.5 ng/mL for stimulated thyroglobulin and more than 2.5 metastatic nodes, and combining the two variables pushed the area under the curve to 0.768. Multivariable analysis in this group ultimately retained stimulated thyroglobulin, thyroglobulin antibody, and iodine-131 activity as factors associated with structural incomplete response.

The intermediate-high/high risk group told a different story. Here, stimulated thyroglobulin, the number of metastatic lymph nodes, the total number of nodes removed, the lymph node ratio, thyroglobulin antibody, and treatment dose all reached statistical significance on univariate testing. ROC-derived cutoffs were 11.625 ng/mL for stimulated thyroglobulin and 11.5 metastatic nodes, with the combination achieving an area under the curve of 0.786. Multivariable logistic regression distilled these down to three independent predictors: stimulated thyroglobulin, the number of metastatic lymph nodes, and the total number of nodes examined. Notably, each additional metastatic node raised the odds of structural incomplete response by 23 percent, while each additional node examined was modestly protective—an effect the authors attribute to more thorough surgical and pathological staging.

The most clinically consequential part of the study, however, focused on the intermediate-risk “grey zone,” the population in which the decision to administer radioactive iodine remains most contested. From 396 intermediate-risk patients—defined as those with recurrence risks between 10 and 30 percent under the 2025 framework—the team randomly partitioned 297 into a training set and 99 into a validation set. Five variables emerged as independent predictors of structural incomplete response in the training cohort: age, tumor size, the number of lymph node metastases, the lymph node ratio, and stimulated thyroglobulin. Each carried a biologically plausible signal. Older patients tend to have reduced radioiodine avidity; larger tumors reflect greater burden; and nodal metrics quantify the extent of metastatic disease.

From these five predictors the investigators constructed a nomogram, a point-based graphical calculator that clinicians can use at the bedside. ROC analysis supplied practical thresholds: more than 8.5 metastatic lymph nodes, stimulated thyroglobulin above 7.46 ng/mL, a lymph node ratio exceeding 0.30, age over 42.5 years, and tumor size greater than 1.05 cm. A physician scores each factor, sums the points, and reads off the patient’s individualized probability of structural incomplete response. In the training cohort the model achieved an area under the curve of 0.865, and bootstrap internal validation with 1,000 resamples and Harrell optimism correction yielded an optimism-corrected C-statistic of 0.853 with a calibration slope of 0.92—evidence of minimal overfitting. Variance inflation factors all fell below 1.1, and the two nodal variables were only weakly correlated, supporting the retention of both.

Discrimination slipped to 0.733 in the held-out validation set, though the authors note the confidence intervals overlap with the training estimate. Decision curve analysis added a further layer of reassurance: across threshold probabilities from 1 to 95 percent, the nomogram’s standardized net benefit exceeded both the treat-all and treat-none strategies, meaning that using the model to guide decisions would, in theory, improve clinical outcomes compared with indiscriminate approaches. Calibration curves in both cohorts showed good agreement between predicted and observed event rates, and the events-per-variable ratio of 12 met accepted standards for logistic regression modeling.

The findings dovetail with a growing body of literature on thyroglobulin dynamics and nodal burden. Prior work has shown that when stimulated thyroglobulin stays below 1 ng/mL, structural incomplete response is essentially never observed; between 1 and 10 ng/mL it occurs in fewer than 2 percent of patients; and above 10 ng/mL the rate climbs to more than 40 percent. Because thyroglobulin is produced only by thyroid tissue and its metastases, rising levels signal residual or recurrent cellular activity. Similarly, the lymph node ratio—positive nodes divided by nodes removed—has repeatedly been linked to poorer disease-specific and overall survival, with a cutoff near 0.3 emerging in earlier studies as prognostically meaningful. The Soochow team’s threshold of 0.30, with 50 percent sensitivity and 93 percent specificity, aligns closely with that precedent.

The authors are candid about the study’s limitations. It was retrospective and single-center, raising the specter of selection bias; the administered iodine-131 activity partly reflects disease severity rather than an independent cause of outcome; dichotomizing continuous predictors discards information; and, crucially, the cohort comprised only patients already selected for radioactive iodine, so the nomogram predicts response within treated patients rather than informing whether therapy should be given at all. External multicenter validation is required before routine clinical use. Still, the contribution is clear: by comparing the determinants of structural incomplete response across ATA risk strata and integrating them into a calibrated, decision-analytically validated tool, the study gives clinicians a way to bring quantitative precision to one of thyroid oncology’s most stubborn gray areas—potentially sparing lower-risk patients unnecessary radiation while intensifying surveillance for those most likely to harbor residual disease.

Subject of Research: Development of a nomogram predicting structural incomplete response to radioactive iodine therapy in intermediate-risk papillary thyroid carcinoma

Article Title: Prognostic Factor Analysis for Risk‐Stratified Papillary Thyroid Carcinoma and Nomogram Development for Predicting Structural Incomplete Response to Radioactive Iodine Therapy in Intermediate‐Risk Patients

Article References: Li, Y., He, Z., Zhao, M., & Zhang, B. (2026). Prognostic Factor Analysis for Risk‐Stratified Papillary Thyroid Carcinoma and Nomogram Development for Predicting Structural Incomplete Response to Radioactive Iodine Therapy in Intermediate‐Risk Patients. Cancer Reports, 9(9), Article e70692. https://doi.org/10.1002/cnr2.70692

Image Credits: AI Generated

DOI: 10.1002/cnr2.70692

Keywords: papillary thyroid carcinoma, radioactive iodine therapy, structural incomplete response, nomogram, thyroglobulin, lymph node metastasis, lymph node ratio, ATA risk stratification, thyroid cancer prognosis, risk prediction model, iodine-131 ablation, decision curve analysis

This comprehensive study leveraged real-world data from over 101,000 patients identified within the Surveillance, Epidemiology, and End Results Program (SEER) database, a robust nationwide cancer registry in the United States. The investigators stratified cohorts based on histological classification—classical papillary thyroid cancer (PTC), aggressive variants of PTC, follicular thyroid cancer (FTC), and minimally invasive FTC—and further categorized patients by their initial recurrence risk into very low, low, intermediate, and high risk. This stratification allowed for nuanced analysis of relative survival, which compares survival of cancer patients to that of matched individuals without cancer, offering a refined measure of treatment impact.

The findings reveal a significant survival advantage in patients who underwent RAI therapy across most subgroups, challenging prior clinical controversies. Particularly striking was the observed relative survival benefit of up to 30.9% in the high-risk differentiated thyroid cancer population, reaffirming the established therapeutic value of RAI in aggressive disease settings. Moreover, even in low- and intermediate-risk groups, where the role of RAI had been less clear, subtle but consistent trends favored RAI intervention. Classical PTC patients with larger tumors or lymph node metastases experienced a 1.3% to 2.0% increase in 10-year relative survival when treated with RAI. Notably, low-risk minimally invasive FTC patients showed a positive survival tendency, hinting that RAI’s protective effects may extend beyond traditionally indicated populations.

Mechanistically, radioactive iodine therapy exploits the physiological uptake of iodide by thyroid tissue, delivering targeted radiation to residual thyroid cancer cells or micrometastases post-thyroidectomy. This targeted cytotoxicity is critical in eradicating occult disease and preventing recurrence. While RAI use has been standardized for high-risk differentiated thyroid cancers, the heterogeneity in tumor biology and disease course in lower-risk groups has fueled divergent clinical guidelines and practices. This study’s extensive evaluation of histologic subtypes and risk categories helps bridge these gaps, providing data-driven insights to inform precision medicine approaches.

It is also noteworthy that the research indicates no detrimental survival effect associated with RAI treatment in any subgroup analyzed. This finding addresses important safety considerations and risk-benefit assessments clinicians must undertake when recommending adjuvant therapies. Furthermore, the improved survival trends become more pronounced approximately eight years after treatment, emphasizing the necessity for long-term follow-up in thyroid cancer survivorship studies.

The implications of these results extend into clinical decision-making and guideline development. As Dr. Henning Weis, lead investigator and nuclear medicine physician at University Hospital Cologne, emphasized, real-world evidence derived from large datasets such as SEER can be pivotal in resolving controversies where randomized controlled trials might be impractical. These insights are particularly valuable given the slow-growing nature of differentiated thyroid cancer and the challenges in accruing long-term survival data.

Additionally, co-author Professor Matthias Schmidt highlighted the substantial investment of nearly a decade in developing comprehensive thyroid cancer treatment guidelines. The current analysis represents a cornerstone, providing empirical substantiation on the survival impact of RAI therapy across diverse patient populations. These findings empower nuclear medicine and endocrine specialists to tailor treatment plans more confidently, balancing potential benefits with clinical nuances inherent to individual cases.

Beyond survival benefits, RAI therapy’s role in reducing recurrence rates has been well established in high-risk differentiated thyroid cancers. This study’s confirmation of survival advantages underscores the dual impact of RAI on disease control and mortality outcomes. Importantly, the research suggests a paradigm shift in considering adjuvant RAI therapy even in patients with low- or intermediate-risk profiles, provided a thorough assessment of tumor characteristics and patient-specific factors.

While the study’s retrospective nature and reliance on registry data introduce certain limitations inherent to observational analyses, its scale, methodological rigor, and comprehensive risk stratification enhance the robustness of the conclusions. Ongoing research integrating molecular and genetic tumor profiling alongside clinical parameters will likely further refine individualized therapeutic strategies in differentiated thyroid cancer.

In conclusion, this landmark investigation delineates a clear survival advantage conferred by radioactive iodine therapy following surgical intervention in differentiated thyroid cancer patients across various histologic subtypes and risk groups. It challenges existing paradigms, especially concerning low- to intermediate-risk cases, and provides a valuable evidence base to guide clinical practice in nuclear medicine and endocrinology. The balance between maximizing therapeutic benefit while minimizing overtreatment remains critical, but these findings mark a significant advance in understanding RAI therapy’s role within precision oncology for thyroid cancer.

Subject of Research: Impact of radioactive iodine treatment on long-term relative survival in differentiated thyroid cancer patients stratified by histologic subtypes and recurrence risk categories.

Article Title: Open Access Impact of Radioactive Iodine Treatment on Long-Term Relative Survival in Patients with Papillary and Follicular Thyroid Cancer: A SEER-Based Study Covering Histologic Subtypes and Recurrence Risk Categories

News Publication Date: April 1, 2025

Web References:

• DOI link to the original article
• The Journal of Nuclear Medicine (JNM)

References:
Weis H, Weindler J, Schmidt K, Drzezga A, Schmidt M, Hellmich M. Impact of Radioactive Iodine Treatment on Long-Term Relative Survival in Patients with Papillary and Follicular Thyroid Cancer: A SEER-Based Study Covering Histologic Subtypes and Recurrence Risk Categories. J Nucl Med. 2025 Apr; (Epub ahead of print).

Image Credits: Images created by Henning Weis, PhD, MD, and Prof. Matthias Schmidt, MD, FEBNM, Department of Nuclear Medicine, University Hospital of Cologne.

Keywords: Thyroid cancer, Radioiodine therapy, Differentiated thyroid cancer, Papillary thyroid cancer, Follicular thyroid cancer, Relative survival, SEER database, Nuclear medicine, Cancer treatment, Precision medicine, Endocrine oncology, Radioactive iodine, Long-term survival